Epsilcapramine en es it fr

Epsilcapramine Brand names, Epsilcapramine Analogs

Epsilcapramine Brand Names Mixture

  • No information avaliable

Epsilcapramine Chemical_Formula


Epsilcapramine RX_link


Epsilcapramine fda sheet

Epsilcapramine FDA

Epsilcapramine msds (material safety sheet)

Epsilcapramine MSDS

Epsilcapramine Synthesis Reference

No information avaliable

Epsilcapramine Molecular Weight

131.173 g/mol

Epsilcapramine Melting Point

205 oC

Epsilcapramine H2O Solubility

5.05E+005 mg/L

Epsilcapramine State


Epsilcapramine LogP


Epsilcapramine Dosage Forms

Solution for injection (containing 250 mg/mL of aminocaproic acid) and tablets (500, 1000mg)

Epsilcapramine Indication

For use in the treatment of excessive postoperative bleeding.

Epsilcapramine Pharmacology

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

Epsilcapramine Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

Epsilcapramine side effects and Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

Epsilcapramine Patient Information

Epsilcapramine Organisms Affected

Humans and other mammals